Print PDF

Sheppard Mullin Represents Tiziana Life Sciences in Follow-On Offering


Sheppard Mullin represented client Tiziana Life Sciences (Tiziana) in a follow-on offering of its American Depositary Shares (ADSs) raising approximately $57.25 million.  Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA & UK AIMS: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases. Tiziana intends to use the net proceeds received from this Offering (i) to advance the clinical development of Foralumab, (ii) to initiate a trial in HCC patients with Milciclib, (iii) to expedite clinical development of TZLS-501 for coronavirus COVID-19, and for working capital and other general corporate purposes.

The Sheppard Mullin deal team representing Tiziana was led by partner Jeff Fessler and included associate Justin Anslow.

Click here to read the press release.


Practice Areas


Jump to Page

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.